Loading...
Market
How will Johnson & Johnson's stock price change by the end of 2024 following Rybrevant's approval?
2
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by 5% to 10% • 25%
Increase by less than 5% • 25%
Decrease or no change • 25%
Stock market data from reputable financial sources like Bloomberg or Yahoo Finance
Story
Johnson & Johnson's Rybrevant Approved for EGFR-Mutated NSCLC, Reduces Progression Risk by 50%
Sep 20, 2024, 09:56 AM
Rybrevant (amivantamab-vmjw), developed by Johnson & Johnson, has received FDA approval in the U.S. for the treatment of second-line EGFR-mutated advanced lung cancer (NSCLC). This approval marks the third new indication for Johnson & Johnson in 2024. Rybrevant, in combination with standard of care, is the first and only targeted regimen to reduce the risk of disease progression by more than 50% in patients with EGFR ex19del/L858R substitution mutations after progression on or after EGFR TKI (MARIPOSA-2). Johnson & Johnson aims to achieve $5 billion in sales for Rybrevant.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Above $175 • 25%
Between $150 and $175 • 25%
Between $125 and $150 • 25%
Below $125 • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increase by 10% or more • 25%
Increase by less than 10% • 25%
No significant change • 25%
Decrease • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%